Open Access iconOpen Access

ARTICLE

PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis

HAN WANG, YINGYING ZHOU, SIYANG ZHANG, YA QI, MIN WANG*

Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical University, Shenyang, China

* Corresponding Author: MIN WANG. Email: email

Oncology Research 2021, 29(4), 275-289. https://doi.org/10.32604/or.2022.03561

Abstract

Metastasis and paclitaxel (PTX) resistance are the main reason for the poor prognosis of ovarian cancer (OC). Evidence showed that RNA-binding proteins (RBPs) and long noncoding RNAs (lncRNAs) can modulate post-transcriptional regulation. The aim of this study was to determine the relationship among RBP, lncRNA and OC and to further guide clinical therapy. Immunohistochemistry revealed that pre-mRNA processing factor 6 (PRPF6) was upregulated in OC chemoresistant tissues and was closely related to advanced (Federation of International of Gynecologists and Obstetricians) FIGO stages and chemo-resistance. PRPF6 promoted progression, and PTX resistance in vitro and in vivo. And the transcripts of small nucleolar RNA host gene SNHG16-L/S were differentially expressed in OC cells and tissues as detected through real-time PCR (RT-PCR). SNHG16-L/S had opposite effects on progression and PTX resistance in OC. Mechanistically, SNHG16-L inhibited GATA-binding protein 3 (GATA3) transcription by binding to CCAAT/enhancer-binding protein B (CEBPB). Moreover, PRPF6 induced the alternative splicing of SNHG16, causing downregulation of SNHG16-L and, leading to the upregulation of GATA3 expression to further promote metastasis and PTX-resistance in OC. Totally, these data unveiled that PRPF6 promotes metastasis and PTX resistance of OC through SNHG16-L/CEBPB/GATA3 axis, which provides a new direction for OC treatment.

Keywords

Ovarian cancer; PRPF6; SNHG16; Paclitaxel resistance; GATA3

Cite This Article

APA Style
WANG, H., ZHOU, Y., ZHANG, S., QI, Y., WANG, M. (2021). PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis. Oncology Research, 29(4), 275–289. https://doi.org/10.32604/or.2022.03561
Vancouver Style
WANG H, ZHOU Y, ZHANG S, QI Y, WANG M. PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis. Oncol Res. 2021;29(4):275–289. https://doi.org/10.32604/or.2022.03561
IEEE Style
H. WANG, Y. ZHOU, S. ZHANG, Y. QI, and M. WANG, “PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis,” Oncol. Res., vol. 29, no. 4, pp. 275–289, 2021. https://doi.org/10.32604/or.2022.03561



cc Copyright © 2021 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 2670

    View

  • 1326

    Download

  • 0

    Like

Share Link